Last reviewed 2026-04-22 · How we verify

(D) DWC202206

DWC202206 is an investigational therapeutic in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action is not publicly disclosed.

At a glance

Mechanism of action

Without access to detailed clinical trial data or company disclosures, the precise molecular target and mechanism remain unknown. Phase 3 status indicates the drug has demonstrated sufficient efficacy and safety in earlier trials to warrant large-scale clinical evaluation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• (D) DWC202206 CI brief — competitive landscape report
• (D) DWC202206 updates RSS · CI watch RSS
• Daewoong Pharmaceutical Co. LTD. portfolio CI